nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-B00E441C·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Endocrinology, Diabetes and Metabolism·Basis: Full text·Type: Observational cohort study

Body weight and waist circumference are differentially associated with the response to L-thyroxine treatment in primary hypothyroidism.

Funkquist et al.Funkquist, Sjöberg, Zetterberg et al.·2026·Journal of clinical & translational endocrinology·10.1016/j.jcte.2026.100440 ↗

Primary claim

The marked correlations with CSF levels of thyroxine and ORX suggest that hypothalamic mechanisms participate in the regulation of WC and weight during L-thyroxine therapy

Tentative · hypothalamic mechanism is not identified by correlations from a 15-person observational cohort
In brief

Rare paired CSF measurements generate useful metabolic hypotheses, but unstable modeling in 15 completers prevents reliable mechanistic inference.

ReliabilityCaveats4 of 4 checks completeRead the 3 entries ↓
Fragile — the claim's weakest requirement is that it works through the path described. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BACKGROUND: Thyroid hormones (TH) and neurotransmitter orexin (ORX) are implicated in the regulation of metabolism. Abdominal weight gain is common in primary hypothyroidism (PH).

METHODS: Our aim was to investigate whether TH affected peripheral weight gain, waist circumference (WC) and low-density lipoprotein cholesterol (LDL-C), before and 6 months after L-thyroxine substitution therapy. A secondary aim was to investigate the role of ORX.

RESULTS: Weight gain was positively correlated with improvement in QoL (r = 0.72, p = 0.003) and with CSF ORX levels in the 15 included patients (r = 0.78, p = 0.001). Increased WC, which was not associated with QoL changes, correlated negatively with free thyroxine levels, after 6 months of treatment, in both CSF (r = -0.71, p = 0.003) and serum (r = -0.64, p = 0.0097). Increased LDL-C correlated negatively with CSF free thyroxine levels after 6 months of treatment (r = -0.74, p = 0.003).

CONCLUSION: The marked correlations with CSF levels of thyroxine and ORX suggest that hypothalamic mechanisms participate in the regulation of WC and weight during L-thyroxine therapy, highlighting the need for individualized treatment of the metabolic disturbances seen in PH.

SHORT COMMUNICATION: Through evaluating the dynamics of body weight and waist circumference during the initial treatment of primary hypothyroidism, a positive correlation was found between orexin levels in CSF and the change in body weight. Furthermore, negative correlations were found between CSF free thyroxine levels and the changes in waist circumference and serum LDL-C levels. These findings emphasize the importance of finding future individualized treatment strategies in primary hypothyroidism, particularly regarding metabolic disturbances.

Key Claims

Primary finding · Tentative

The marked correlations with CSF levels of thyroxine and ORX suggest that hypothalamic mechanisms participate in the regulation of WC and weight during L-thyroxine therapy

Fragile — the claim's weakest requirement is that it works through the path described. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

hypothalamic mechanism is not identified by correlations from a 15-person observational cohort

Abstract, Conclusion
Quote verified
Secondary · Supported

Weight gain was positively correlated with CSF ORX levels in the 15 included patients (r = 0.78, p = 0.001).

large reported correlation with baseline orexin, limited by sample size and exploratory multiple testing

Abstract, Results; Results, Change in Body Weight; Figure 4
Secondary · Supported

Increased WC correlated negatively with free thyroxine levels, after 6 months of treatment, in both CSF (r = -0.71, p = 0.003) and serum (r = -0.64, p = 0.0097).

reported bivariate associations are directionally consistent, though the small cohort and multiplicity limit precision

Abstract, Results; Results, Change in Waist Circumference; Figure 2
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Rare paired cerebrospinal-fluid measurements

Thyroid hormones and orexin were measured through lumbar puncture before and during treatment, providing longitudinal human observations that are uncommon in this field.

↳ Methods, Sampling of Blood and CSF; Discussion, Strengths of the Study

#methodological rigour

Standardized sampling and biochemical procedures

Blood and CSF were collected after fasting at consistent morning times, samples were analyzed in the same run, and the orexin analyst was blinded to clinical data.

↳ Methods, Sampling of Blood and CSF; Biochemical Procedures

#contribution

Weight and waist treated separately

The analysis distinguishes total weight change from waist-circumference change and reports that they were not correlated, clarifying that the outcomes may reflect different processes.

↳ Results, Change in Waist Circumference; Change in Body Weight; Discussion, Waist Circumference Dynamics

Limitations

#methodological rigour

Adjusted waist model changes specification

Statistical Methods specifies a ΔWC model using ΔCSF f-T4, Δweight, and age, whereas Results and Table 2 report visit-two CSF f-T4 and a dose interaction. This unresolved discrepancy affects the central adjusted waist-circumference result.

↳ Statistical Methods; Results, Change in Waist Circumference; Table 2

#methodological rigour

Regression models exceed available information

With only 15 completers, backward selection produced models containing several predictors and interactions with reported R² values of 0.60–0.82. The described bootstrap validation is not accompanied by optimism-corrected results.

↳ Methods, Statistical Methods; Results, Table 2

#reporting

Mechanistic claims exceed observational evidence

The paper interprets correlations as evidence that hypothalamic changes play a crucial role and that L-thyroxine may not address them fully. The cohort design and concurrent visit-two measurements cannot establish those mechanisms.

↳ Abstract, Conclusion; Discussion, Effects of Orexin on Metabolism; Practical Implications

Does this match your read? Add your assessment ↓

Nabu Commentary

The rare paired-CSF design and standardized morning sampling support a genuine but preliminary contribution. Methodological Rigour is the limiting dimension because 15 completers support regression models with several selected predictors and interactions, while 10 initial participants did not return for follow-up. The mismatch between the ΔWC model specified in Statistical Methods and the model reported in Results and Table 2 creates a material reliability concern. The simple correlations are best treated as exploratory signals, while the hypothalamic and individualized-treatment interpretations exceed what this observational design identifies.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.6±0.2

Contribution
3.3

Repeated CSF thyroid-hormone and orexin measurements before and during treatment provide an unusual human dataset and a genuine hypothesis-generating advance. The contribution remains preliminary because it rests on 15 completers without replication.

Methods, Sampling of Blood and CSF; Results, Figures 2–5; Discussion, Strengths of the Study

There are very few studies—regardless of the disease being examined—that have performed two lumbar punctures on the same individuals

Methodological Rigour
2.0

Standardized fasting morning sampling, same-run assays, and blinded orexin measurement support execution, but data-driven regression selection with up to five terms in 15 patients creates substantial instability. Confounding, concurrent visit-two measurements, attrition, and mechanistic interpretation activate a stacked serious ceiling.

Methods, Statistical Methods and Biochemical Procedures; Results, Table 2; Methods, Study Population

This regression model was further utilized in the rms::fastbw() function, which iteratively removed variables with p-values exceeding 0.2.

Reporting
3.0

The manuscript has a followable methods-results-discussion sequence and reports the principal correlations directly. Its Abstract conclusion and Practical Implications nevertheless translate observational correlations into hypothalamic and treatment claims that imply stronger evidence than the design supplies.

Abstract, Conclusion; Conclusions; Practical Implications

intrinsic hypothalamic changes play a crucial role in the disease course

Positioning
2.7

The discussion engages prior thyroid, orexin, weight, and waist-circumference literature and names the small sample and missing behavioral measurements. Contextual handling is reduced because the paper then infers that diet, activity, and sleep did not influence orexin and does not trace the small sample through its strong conclusions.

Discussion, paragraph 2; Limitations; Conclusions and Practical Implications

the participants did not exhibit any influence on ORX from possible changes in diet, physical activity or sleep habits

Reliability

Caveats4 of 4 checks


Results checkNoted

One reported value does not reconcile, but the key claims do not rest on it.

Reporting and transparencyNoted

The ΔWC regression specification differs between Methods and Results, the displayed thyroid-hormone p-values are not identified as raw or Holm-adjusted, and bootstrap validation is described without reported validation results. These are reporting gaps; their effects on the estimates cannot be determined from the supplied text.

Conflict of interest: declared · Ethics approval: declared · Preregistration: not stated · Data availability: not stated · Code availability: not stated

Reference IntegrityNoted

54 references in manuscript 54 of 54 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Metabolic and endocrine · Endocrine, metabolic, blood, and immune disorders
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesCatch-all cause
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim rests on correlations in a single observational cohort of only fifteen patients with no controlled intervention or independent confirmation.

From the paper
“highlighting the need for individualized treatment of the metabolic disturbances seen in PH”

The paper names a possible real-world use, individualized treatment of metabolic disturbances, but does not specify who would act on the findings or in what setting.

Pathway

Endocrinologists treating hypothyroid patients could eventually use central thyroid and orexin markers to tailor L-thyroxine dosing and manage metabolic changes individually.

Barrier

The evidence is correlational from a very small single-centre cohort, and the proposed markers require invasive lumbar puncture, so findings need replication and practical measurement alternatives.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Iodine concentration of organic and conventional milk: implications for iodine intake

    Bath, Button, Rayman · 2011 · Health sciences

    Primary claim

    Organic milk was 42·1 % lower in iodine content than conventional milk (median iodine concentration 144·5 v. 249·5 ng/g; P < 0·001).

    Supported
    Evidence Score
    3.8±0.1
    Reliability
    Caveats
  2. Iodine fortification of foods and condiments, other than salt, for preventing iodine deficiency disorders

    Joseph Alvin Santos, Anthea Christoforou, Kathy Trieu, et al. · 2019 · Health sciences

    Primary claim

    Pooled results from RCTs showed that urinary iodine concentration significantly increased following iodine fortification (SMD 0.59, 95% CI 0.37 to 0.81; 6 RCTs, 2032 participants; moderate-quality evidence).

    Supported
    Evidence Score
    4.2±0.1
    Reliability
    Caveats
  3. Reframing menopause and menopause hormone therapy as opportunities for healthy aging

    Laura L. Gravelsins, Mateja Perović, Madeline Wood Alexander, et al. · 2026 · Clinical medicine

    Primary claim

    menopause characteristics, such as type, timing, and symptom burden, influence health outcomes and later-life disease risk

    Supported
    Evidence Score
    3.2±0.2
    Reliability
    Caveats

How the rubric works →